Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A. H. ROBINS' DIMETAPP PACES CONSUMER PRODUCTS GROWTH, CLIMBS 45.1% IN 1991 TO $132 MIL.; WHITEHALL LABS' PREPARATION H SALES ARE UP 15.5% TO $82 MIL.

Executive Summary

American Home Products' A. H. Robins division generated $132 mil. in Dimetapp revenues in 1991, up 45.1% from the year earlier, according to the AHP "1992 Fact Book" (see box for breakdown of American Home Products' consumer health care sales by product). Dimetapp is the "brand most widely recommended by physicians in the United States for treatment of uncomplicated colds," AHP said in its 1991 annual report. During the year, the firm renamed the multisymptom flu product Dimetapp Plus as Dimetapp Cold and Flu. Robins also added a new larger size of Dimetapp-DM for colds accompanied by coughs. The Dimetapp family of products was the fastest-growing product line at Robins for the year, trailed closely by Robitussin, which was ahead 43.8% to $174 mil. Robins made a number of Robitussin expansions in 1991: the company introduced a "maximum strength cough" formula, a pediatric cough and cold formula, and Robitussin cough drops "in three flavors in bag and stick forms." The cough drop product "rapidly received consumer acceptance," the AHP annual report notes. Overall, Robins consumer health sales totaled $443 mil., up 29.5% from the year earlier. The Robins franchise accounted for just under a third of AHP's total consumer health sales, with Whitehall Labs generating revenues of $1.1 bil., up 3.7%. "Significantly higher" sales for Whitehall's Advil OTC ibuprofen helped drive a 12.7% gain in the analgesics sector to $504 mil., Whitehall's largest product group. The "second-largest selling U.S. analgesic," Advil benefited from "new advertising, increased media support, and heavier physician detailing and sampling efforts," according to the annual report. The gain in analgesic sales actually represents a rebound to 1989 levels when analgesics brought in $511 mil. That figure plunged $64 mil. (off 12.5%) in 1990. Sales of Preparation H gained 15.5% for the year to $82 mil., making it the third largest consumer product sold by Whitehall behind analgesics and toothpaste. FDA recently informed Whitehall that its data for Preparation H are inadequate to support claims for relief of hemorrhoidal symptoms, and that there is no data backing claimed effectiveness for shrinking of hemorrhoidal tissue ("The Pink Sheet" March 30, T&G-1). At $82 mil., Preparation H accounted for 7.3% of Whitehall's 1991 sales, and 5.3% of total consumer health care revenues for the year. The whole health care business (prescription drugs, consumer health products and medical supplies) produced operating profits of $1.56 bil. on sales $6.22 bil. (a 25% operating profit ratio).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel